Genomic profile of human meningioma cell lines by Mei, Yu et al.















See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Mei, Yu; Bi, Wenya Linda; Greenwald, Noah F.; Agar, Nathalie Y.; Beroukhim, Rameen; Dunn, Gavin P.; and Dunn, Ian F., ,"Genomic
profile of human meningioma cell lines." PLoS One.12,5. e0178322. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5933
Authors
Yu Mei, Wenya Linda Bi, Noah F. Greenwald, Nathalie Y. Agar, Rameen Beroukhim, Gavin P. Dunn, and Ian F.
Dunn
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/5933
RESEARCH ARTICLE
Genomic profile of human meningioma cell
lines
Yu Mei1, Wenya Linda Bi1,2,3, Noah F. Greenwald1,2,3, Nathalie Y. Agar1,2,
Rameen Beroukhim2,3,4, Gavin P. Dunn5, Ian F. Dunn1,4*
1 Center for Skull Base and Pituitary Surgery, Department of Neurosurgery, Brigham and Women’s Hospital,
Harvard Medical School, Boston, Massachusetts, United States of America, 2 Department of Cancer Biology,
Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, 3 Broad Institute of MIT
and Harvard, Cambridge, Massachusetts, United States of America, 4 Department of Medical Oncology,
Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, 5 Department of
Neurosurgery, Pathology, and Immunology, Center for Human Immunology and Immunotherapy Programs,
Washington University School of Medicine, St. Louis, Missouri, United States of America
* idunn@partners.org
Abstract
Meningiomas, derived from arachnoid cap cells, are the most common intracranial tumor.
High-grade meningiomas, as well as those located at the skull base or near venous sinuses,
frequently recur and are challenging to manage. Next-generation sequencing is identifying
novel pharmacologic targets in meningiomas to complement surgery and radiation. How-
ever, due to the lack of in vitro models, the importance and implications of these genetic vari-
ants in meningioma pathogenesis and therapy remain unclear. We performed whole exome
sequencing to assess single nucleotide variants and somatic copy number variants in four
human meningioma cell lines, including two benign lines (HBL-52 and Ben-Men-1) and two
malignant lines (IOMM-Lee and CH157-MN). The two malignant cell lines harbored an ele-
vated rate of mutations and copy number alterations compared to the benign lines, consis-
tent with the genetic profiles of high-grade meningiomas. In addition, these cell lines also
harbored known meningioma driver mutations in neurofibromin 2 (NF2) and TNF receptor-
associated factor 7 (TRAF7). These findings demonstrate the relevance of meningioma cell
lines as a model system, especially as tools to investigate the signaling pathways of, and
subsequent resistance to, therapeutics currently in clinical trials.
Introduction
Meningiomas, arising from the meninges surrounding the brain and spinal cord, account for
a third of all primary brain tumors [1]. The World Health Organization (WHO) classifies
meningiomas into three grades, with increasing grade corresponding to increasing proclivity
for invasion and recurrence. Grade I meningiomas are frequently curable with surgery. How-
ever, a subset located at the skull base, adjacent to major venous sinuses, or insinuated around
major neurovascular structures pose challenges to complete resection. Furthermore, meningi-
omas of higher grades frequently recur despite surgery and radiation, with no effective alterna-
tive pharmacologic treatments.
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Recently, an increasing understanding of the genomic basis underlying meningiomas have
opened potential therapeutic targets for recurrent or progressive tumors [2–6]. In addition to
mutation or loss of neurofibromin 2 (NF2), recurrent mutations in v-akt murine thymoma viral
oncogene homolog 1 (AKT1) and v-akt murine thymoma viral oncogene homolog 3 (AKT3),
phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA), TNF receptor-associated factor
7 (TRAF7), smoothened (SMO), krupplelike factor 4 (KLF4), SWI/SNF related, matrix associated,
actin dependent regulator of chromatin, subfamily b, member 1 (SMARCB1), RNA polymerase II
subunit A (POLR2A), telomerase reverse transcriptase (TERT) promoter, BRCA1 Associated Pro-
tein 1 (BAP1), and homolog of suppressor of fused (SUFU) have been identified within subsets of
meningiomas [2–7]. Furthermore, the burden of chromosomal gains and losses, or copy num-
ber status, of atypical meningiomas has been associated with recurrence risk [8]. However, the
impact of these mutations and chromosomal instability on tumor initiation and progression
remain incompletely defined, in part due to a lack of effective in vitro models for meningioma.
Meningioma cell lines with canonical oncogenic mutations or genome disruption may
serve as effective model systems to interrogate the biological consequences of initiating geno-
mic alterations and their inhibition. Thus, we profiled the exomes of four common meningi-
oma cell lines to determine the representation of characteristic meningioma genomic features
suitable for targeted investigations.
Methods
Human meningioma cell line culture
We profiled four established human meningioma cell lines, including two benign lines (HBL-
52 and Ben-Men-1) and 2 malignant lines (IOMM-Lee and CH157-MN). The two benign
meningioma cell lines were purchased from CLS Cell Lines Service (Eppelheim, Germany)
and DSMZ (Braunschweig, Germany) respectively. CH157-MN was courtesy of Dr. Yancey
Gillespie (University of Alabama-Birmingham), and IOMM-Lee was courtesy of Dr. Randy
Jensen (University of Utah). All cell lines, except HBL-52, were cultured in growth media
including Dulbecco’s Modified Eagle Medium (DMEM), 10% fetal bovine serum, 2mM L-Glu-
tamine, 100 IU/mL of penicillin and 100 μg/mL of streptomycin (Life Technology, Grand
Island, NY). HBL-52 was cultured in McCoy’s 5A medium (Fisher scientific, Pittsburgh, PA)
supplemented with 2mM L-Glutamine, 10% fetal bovine serum, 100 IU/mL of penicillin and
100 μg/mL of streptomycin. Cultured cells were maintained at 37˚ in a 5% CO2 atmosphere.
DNA isolation
Human meningioma cells were cultured in T25 flask until confluence, washed with PBS, tryp-
sinized in 0.25% Trypsin/EDTA (Life Technology, Grand Island, NY), and suspended in PBS.
DNA was isolated using the QIAamp DNA mini kit (Qiagen, Valencia, CA) according to the
manufacturer’s protocol. The concentration of double-stranded DNA was quantified using an
Epoch Spectrophotometer (BioTek, Winooski, VT).
Next-generation sequencing
Whole exome sequencing (WES) was performed at the Broad Institute and the Center for Can-
cer Genome Discovery at the Dana-Farber Cancer Institute, as described previously [2, 9].
Briefly, to generate 250bp libraries, 250ng/ul of purified DNA was randomly fragmented by
Covaris sonication (Covaris, Woburn MA), followed by purification using Agencourt AMPure
XP beads (Beckman Coulter, Inc., Indianapolis, IN) and ligation to DNA barcoded adaptors
(Illumina TruSeq, Illumina Inc., San Diego, CA). Exome hybrid capture was performed with
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Methyltransferase-Like; BAP1, BRCA1 Associated
Protein 1; BARD1, BRCA1 Associated RING
Domain 1; CDKN2A, cyclin dependent kinase
inhibitor 2A; CRIPAK, cysteine-rich PAK1 inhibitor;
ENAH, enabled homolog (Drosophila); FGF10,
fibroblast growth factor receptor 10; FGF4,
fibroblast growth factor receptor 4; GATK, genome
analysis toolkit; IGV, integrative genomics viewer;
KLF4, krupplelike factor 4; JMJD1C, jumonji
domain containing 1C; LZTR1, leucine zipper like
transcription regulator 1; mTOR, mechanistic
target of rapamycin; NF2, neurofibromin 2; PAK1,
p21 protein-activated kinase 1; PARP1, poly [ADP-
ribose] polymerase 1; PDGFb, platelet derived
growth factor subunit b; PI3K, phosphoinositide 3-
kinase; PIK3CA, phosphoinositide-3-kinase,
catalytic, alpha polypeptide; POLR2A, RNA
polymerase II subunit A; SCNAs, somatic copy-
number alterations; SMARCB1, SWI/SNF related,
matrix associated, actin dependent regulator of
chromatin, subfamily b, me SSPO, SCO-Spondin;
SUFU, suppressor of fused, drosophila, homolog
of; TERT, telomerase reverse transcriptase; TRAF7,
TNF receptor-associated factor 7; VEP, variant
effect predictor; WES, Whole exome sequencing.
Agilent Sure Select All Exon v2.0 hybrid capture kit (Agilent Technologies, Santa Clara, CA).
The 250bp libraries were loaded for paired-end sequencing on Illumina GAIIx (Illumina Inc.,
San Diego, CA). Sample reads were de-multiplexed using Picard tools [10, 11] (http://picard.
sourceforge.net), read pairs were aligned to the hg19 reference sequence (NCBI 37) (ftp://
ftptrace.ncbi.nih.gov/1000genomes/ftp/technical/reference/) using the Burrows-Wheeler
Aligner [12]. Bias in base quality score assignments due to flow cell, lane, dinucleotide context,
and machine cycle were analyzed and recalibrated, and local realignment around insertions or
deletions (indels) was obtained using the Genome Analysis Toolkit (GATK) [13, 14], for gen-
eration of a single BAM file for each cell line for analysis of copy number alterations, muta-
tions, and large-scale structural rearrangements.
Genomic analysis
Single nucleotide variants were called and post-filtered using MuTect v1.1.4 [15], which were
then annotated to genes and compared to events in the Catalogue of Somatic Mutations in
Cancer using Oncotator. Indel calling was achieved using the GATK Somatic Indel Detector
tool. As described previously [10], somatic indels were called from locally realigned data based
on the fraction of supporting reads at a given locus in the tumor cell BAM file. Variants were
characterized as somatic using a CEPH cell line as the normal control. Variants were filtered
against SNP database as well as 1000 Genomes [16]. The resulting variants were input into the
variant effect predictor (VEP) (http://www.ensembl.org/info/docs/tools/vep/index.html) to
predict the consequences of the variants on the protein sequences.
Somatic copy-number alterations (SCNAs) were called using RecapSeg, which performs
local change-point analysis and subsequent merging of adjacent chromosomal segments with
similar copy numbers. The resulting segments were annotated using Oncotator, then visual-
ized using integrative genomics viewer (IGV, http://www.broadinstitute.org/igv/). The SCNAs
across the entire genome were then analyzed by GISTIC 2.0 [17, 18].
Rearrangement detection was performed using dRanger and BreakPointer algorithms [10,
19], and visualized using the Circos program (http://mkweb.bcgsc.ca/circos) [20]. However,
exome sequencing is limited in power to detect rearrangements and few were detected.
Targeted sequencing
Variants identified by WES, as well as selected regions of previously published genes impli-
cated in meningioma (NF2, AKT1, TRAF7, SMO, and KLF4), were analyzed by PCR and
Sanger sequencing. Mutant sites from NF2 (22), TRAF7 (5), AKT1 (1), SMO (2), KLF4 (1), and
TERT (2) were sequenced. DNA from the four meningioma cell lines and one normal human
cell line (293T) were amplified using PCR primers designed to target identified mutations (S1
Table). PCR products were separated by 1% agarose gel, visualized under UV light, extracted
using the Qiagen Gel Extraction Kit (Valencia, CA), and subject to Sanger sequencing (Macro-
gen, Boston, MA). Mutant variants identified by Sanger sequencing were verified by alignment
of sequenced results with sequences of normal human cell line 293T and human genomic
DNA reference (hg19). Furthermore, the TERT promoter region was focally sequenced across
cell lines to assess for presence of TERT mutations, given the important role it may play in
meningioma progression [7, 21].
Results
We performed whole exome sequencing on four human meningioma cell lines (Table 1),
including two from grade I meningiomas (HBL-52 and Ben-Men-1), one from an anaplastic
meningioma (IOMM-Lee), and one from a meningioma resected in 1977 with unclear
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classification (CH157-MN), to characterize copy number alterations, mutations, and indels
[22–25]. We also performed Sanger sequencing to validate identified mutations in known
meningioma driver genes, along with previously identified hotspot mutations in these genes.
Copy number variation in human meningioma cell lines
Arm-level chromosomal alterations are a hallmark of meningiomas, especially high-grade and
angiomatous subtypes. CH157-MN harbored the greatest number of arm-level SCNAs of all
four cell lines, consistent with the pattern observed in high-grade human meningiomas, while
the grade I meningioma cell line HBL-52 harbored no broad copy number alterations (Fig
1A). We identified a number of arm-level gains and losses, including gain of 3p, 3q, 5p, 5q, 9p,
and 13q, and loss of 4p, 4q, 8p, 8q, 15q, 18p,18q and 22q, across individual cell lines (Fig 1A).
These losses span region including important oncogenes and tumor suppressors, including
loss of cyclin dependent kinase inhibitor 2A (CDKN2A) on 9p21.3 in IOMM-Lee (Table 2).
We examined the copy number profile of specific genes within cardinal signaling pathways
implicated in meningioma formation, including the phosphoinositide 3-kinase (PI3K) / mech-
anistic target of rapamycin (mTOR)/AKT and Hedgehog pathways, as well as cysteine-rich
PAK1 inhibitor (CRIPAK) / p21 protein-activated kinase (PAK)/NF2 pathway (Fig 1B). We
found that the PI3K/mTOR/AKT and SMO pathways were activated in 75% of human menin-
gioma cell lines.
Loss of chromosome 22, which contains the known meningioma tumor suppressor NF2,
was observed in Ben-Men-1 and CH157-MN. One negative regulator of Merlin, the protein
product of NF2, is PAK1, which is in turn inhibited by CRIPAK [26, 27]. We observed loss of
CRIPAK in CH157-MN and IOMM-Lee and gain of its possible downstream effectors, PAK1/2
(Fig 1B). Western blot analyses of the meningioma cell lines corroborated high levels of protein
expression of PAK1 and phospho-PAK1 and absence of NF2 in CH157-MN (Fig 1C and 1D).
Mutation analysis in human meningioma cell lines
We identified a total of 2832 variants (mean 708) across the four cell lines, with a significantly
higher number of mutations and indels in the anaplastic cell line IOMM-Lee compared to the
other cell lines (Fig 2A). The most frequent variants were missense mutations and frameshift
indels types across all cell lines (Fig 2B). Recurrent mutations and indels in aquaporin 12B
(AQP12B), acetylserotonin O-methyltransferase-like (ASMTL), CRIPAK, and SCO-Spondin
(SSPO) were identified across the cell lines (Table 3). We also identified mutations in known
meningioma driver genes, including two mutations in NF2 and a TRAF7G536S missense muta-
tion, which were confirmed by Sanger sequencing (Fig 3). We also performed Sanger sequenc-
ing to check for the presence of mutations previously reported in meningioma driver genes,
including regions of NF2, AKT1, TRAF7,KLF4, SMO, and the TERT promoter. However,
apart from the initial three mutations identified via NGS, we did not observe additional
alterations, suggesting that our NGS coverage was sufficient for detection. TERT promoter
Table 1. Characteristics of the human meningioma cell lines.
Cell line WHO grade Location Gender/age (y) Reference
HBL-52 I Optic canal Female, 47 [25]
Ben-Men-1 I Parietal falx Female, 68 [24]
IOMM-Lee III Intraosseous Male, 61 [22]
CH157-MN unknown unknown Female, 41 [23]
WHO, World Health Organization.
https://doi.org/10.1371/journal.pone.0178322.t001
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mutation C228T (c.-124C>T), as assayed by focused sequencing, was observed in CH157-MN
and IOMM-Lee (Table 3).
Chromosome rearrangements in human meningioma cell lines
Although whole-exome sequencing is underpowered to detect chromosomal rearrangements,
we identified 14 rearrangements across the four cell lines (S2 Table). Of note, in CH157-MN
harbored an intrachromosome translocation of jumonji domain containing 1C (JMJD1C) on
Fig 1. Somatic copy-number alterations in human meningioma cell lines. (A) Heatmap of chromosomal gains (red) and losses (blue) across all 22
chromosomes (y-axis) for four meningioma cell lines (x-axis). (B) Focal gains (red) or losses (blue) across gene members of three distinct signaling pathways
(x-axis) for four meningioma cell lines (y-axis). (C) Western blot analysis of phosphorylated and un-phosphorylated PAK1 and NF2. (D) Quantification of
western blot protein expression, p-PAK1 and p-NF2 were normalized to PAK1 and NF2, respectively. PAK1 and NF2 were normalized to loading control β-
actin.
https://doi.org/10.1371/journal.pone.0178322.g001
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chromosome 10, resulting in deletion of this gene, and a fusion of leucine zipper like transcrip-
tion regulator 1 (LZTR1) and FLJ39582 on chromosome 22 (Fig 4).
Discussion
In vitro models have played important roles in furthering our understanding of cancer biology
and treatment paradigms across a range of tumor types. As our understanding has increased
of the impact that molecular classification has on patient response to treatment, it has become
crucial to determine whether model systems accurately recapitulate the disease of interest. We
performed the first whole-exome sequencing of meningioma cell lines to determine their
applicability to the study of meningioma biology.
Recent work has demonstrated that there exist two broad classes of meningiomas based on
their mutational profile: those driven by NF2 inactivation, and those with non-NF2 driver
gene alterations, such as mTOR and Hedgehog pathway alterations [2–5]. Such differences in
tumorigenesis may significantly impact the consequent signaling pathways. We show that two
commonly used cell lines, CH157-MN and Ben-Men-1, harbor deleterious NF2 mutations as
well as chromosome 22 loss. Furthermore, interrogation of signaling partners in the NF2 cas-
cade revealed high levels of PAK1, an upstream oncogene that inactivates NF2 in cancer cells
through phosphorylation [28]. These results suggest that CH157-MN and Ben-Men-1 could
be well suited to study NF2 signaling in meningioma formation. We identified a canonical
mutation in TRAF7 in an additional cell line, HBL-52, which may be more amenable to studies
examining the signaling pathways important in non-NF2 driven tumors.
Table 2. Copy number variations in human meningioma cell lines.
CELL LINE CYTO
BAND
CHROMOSOME TYPE OF CNV GENES AFFECTED
CH157-MN 1q42.11 Chr1:225142802–226187015 1044kb duplication DNAH14,ENAH,EPHX1,LBR,LEFTY1,LEFTY2,SRP9,TMEM63A,SDE2
CH157-MN 1q42.11 Chr1:224606120–224922410 316kb duplication CNIH3
CH157-MN 1q42.11 Chr1:226590082–226925161 335kb duplication PARP1,c1orf95, ITPKB
IOMM- Lee 5p15 Chr5:801281–825368 24kb duplication ZDHHC11
IOMM- Lee 9p21.3 Chr9:21971209–21974828 3.6kb deletion CDKN2A
CH157-MN 12q24.22 Chr12:118504499–118509274 4.7kb deletion VSIG10
https://doi.org/10.1371/journal.pone.0178322.t002
Fig 2. Mutations identified in human meningioma cell lines. (A) Number of mutations (y-axis) detected in each cell line (x-axis). (B) Distribution of coding
consequences from SNV and Indel variants observed in meningioma cell lines.
https://doi.org/10.1371/journal.pone.0178322.g002
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NBPF10 chr1:144220807 Missense_Mutation c.1793A>C p.D598A CH157-MN, Ben-Men-1
SPDYE6 chr7:101988983 Missense_Mutation c.890C>T p.P297L IOMM-Lee, HBL-52, Ben-Men-1
LOC399753 chr10:49218451 Missense_Mutation c.1688C>T p.T563I IOMM-Lee, Ben-Men-1
DDX11L11 chr12:92119 Missense_Mutation c.191A>G p.H64R CH157-MN, HBL-52
TBC1D3P2 chr17:60345508 Nonstop_Mutation c.760T>C p.*254Q CH157-MN, IOMM-Lee, HBL-52
SIGLEC16 chr19:50474960 Missense_Mutation c.14C>G p.A5G HBL-52, Ben-Men-1
KIR2DL2 chr19:35127 Missense_Mutation c.796C>T p.R266C CH157-MN, Ben-Men-1
KIR2DL2 chr19:39293 Missense_Mutation c.52C>A p.P18T CH157-MN, Ben-Men-1
KIR2DL2 chr19:118836 Missense_Mutation c.313A>C p.T105P HBL-52, Ben-Men-1
KIR2DL2 chr19:118856 Missense_Mutation c.333G>T p.L111F HBL-52, Ben-Men-1
AQP12B chr2:241621800–241621800 Frame_Shift_Del c.455delG p.S152fs IOMM-Lee, HBL-52
CRIPAK chr4:1388375–1388376 Frame_Shift_Ins c.76_77insCA p.S26fs CH157-MN, Ben-Men-1
SSPO chr7:149503917–149503920 Splice_Site c.8736_splice p.G2912_splice IOMM-Lee, CH157-MN, HBL-52
LOC399753 chr10:49218408–49218408 Frame_Shift_Del c.1731delC p.N577fs CH157-MN, HBL-52
ASMTL chrx:1522164–1522164 Frame_Shift_Del c.1864delT p.*622fs IOMM-Lee, CH157-MN, HBL-52
TERT chr5:1295228 Missense_Mutation c.-124C>T IOMM-Lee, CH157-MN
https://doi.org/10.1371/journal.pone.0178322.t003
Fig 3. Validation of mutation calls human meningioma cell lines. (A) Table of putative meningioma driver-gene alterations identified from whole-
exome sequencing. (B) Schematic demonstrating validation protocol for each mutation.
https://doi.org/10.1371/journal.pone.0178322.g003
Genetic analysis of human meningioma cell lines
PLOS ONE | https://doi.org/10.1371/journal.pone.0178322 May 26, 2017 7 / 12
We detected no mutations in either AKT1, SMO, or PIK3CA in these four profiled cell lines.
These well-established driver alterations result in activation of pathways that are amenable to
pharmacologic inhibition [2–4], with clinical trials testing inhibitors against these drivers
underway. New in vitro models that replicate these oncogenic pathways are needed to better
understand the unique molecular pathways influenced by these non-NF2 mutations as well as
to investigate mechanisms for acquired resistance with application of targeted inhibitors.
Genomic instability is one of the key differentiators between grade I and grade II-III
meningiomas [29]. Loss of chromosome 22 is the most common arm-level alteration across all
Fig 4. Rearrangements detected in human meningioma cell lines. Circos plots showing intra-chromosomal (green) and inter-
chromosomal (purple) rearrangements between regions of the genome.
https://doi.org/10.1371/journal.pone.0178322.g004
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meningiomas (40–60% in grade I, 75% in grade II-III), along with recurrent loss of chromo-
somes 1p, 6q, 10q, 14q, and 18q, and gain of 1q, 9q, 12q, 15q, 17q and 20q in high-grade
tumors. We found a higher level of genomic disruption in the two cell lines, IOMM-Lee and
CH157-MN, consistent with the original meningioma being of a high-grade nature. Of note,
the pattern of copy number alterations in these cell lines differs from the most commonly
observed altered chromosomal losses and gains in human meningioma, which may reflect
genomic changes over time during in vitro passages or be specific to the original tumors from
which the lines were derived.
We observed a number of potentially oncogenic focal amplifications and deletions. Loss of
chromosome 9p21.3, which harbors the critical tumor suppressor CDKN2A, was observed in
IOMM-Lee, a cell line derived from an anaplastic meningioma. CH157-MN had gain of chro-
mosome 1q, along with a series of focal gene changes on 1q42.11. Chromosome 5 was ampli-
fied in both Ben-Men-1 and IOMM-Lee, with corresponding increase in copy number of
genes associated with vascular development and proliferation, such as platelet derived growth
factor subunit b (PDGFβ), fibroblast growth factor receptor 4 (FGFR4), and fibroblast growth
factor receptor 10 (FGF10). We also detected amplification of both enabled homolog (ENAH)
and poly [ADP-ribose] polymerase 1 (PARP1) in CH157-MN, although these genes have not
previously been implicated in meningiomas tumorigenesis [30, 31].
We previously demonstrated that meningiomas of all grades present with complex rear-
rangement profiles, including frequent observation of complex events such as chromothripsis
and chromoplexy [2]. While whole-exome sequencing is not powered to identify most rear-
rangements, we were able to detect a number of intrachromosomal rearrangements and one
interchromosomal rearrangement, involving genes that have previously been implicated in
tumorigenesis, including BRCA1 Associated RING Domain 1 (BARD1), JMJD1C [32], and
LZTR1. However, none were recurrently rearranged in our cohort, nor have they previously
been shown to be recurrently mutated in meningioma. Further investigation of whole-genome
sequenced meningioma will be necessary to identify oncogenic rearrangements.
In summary, this study identified the aberrance of chromosome structure, focal gene
changes, and somatic single nucleotide variants in human meningioma cell lines. The alter-
ations of these genes might be involved in meningioma progression by affecting cell motility,
cytokinesis, chromatin and epigenomic regulation, immune response, malignant transforma-
tion, or metabolism. Due to the limited meningioma cell lines currently available, much work
remains to complete the mutational catalog of meningiomas to connect recurrent genomic
alterations to altered pathways and acquired cellular vulnerabilities, and their correlation with
disease stratification and prognosis. Moreover, future insights into the molecular mechanisms
of these genetic drivers in meningioma development might inform our understanding of
genome influence on meningioma evolution and therapy.
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